Milestone Pharmaceuticals Inc.

NasdaqGS:MIST Stock Report

Market Cap: US$119.2m

Milestone Pharmaceuticals Management

Management criteria checks 3/4

Milestone Pharmaceuticals' CEO is Joe Oliveto, appointed in Mar 2017, has a tenure of 7.75 years. total yearly compensation is $1.98M, comprised of 30.4% salary and 69.6% bonuses, including company stock and options. directly owns 0.43% of the company’s shares, worth $513.32K. The average tenure of the management team and the board of directors is 3.7 years and 5.7 years respectively.

Key information

Joe Oliveto

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage30.4%
CEO tenure7.8yrs
CEO ownership0.4%
Management average tenure3.7yrs
Board average tenure5.7yrs

Recent management updates

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Jun 07
Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Recent updates

Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?

Nov 06
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Jun 07
Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

Sep 13
Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Mar 07
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Oct 15
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Jun 24
We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Feb 25
We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Aug 25
We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

Apr 02
Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Jan 15
What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Nov 18

Milestone Pharmaceuticals EPS beats by $0.09

Nov 13

CEO Compensation Analysis

How has Joe Oliveto's remuneration changed compared to Milestone Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$43m

Jun 30 2024n/an/a

-US$48m

Mar 31 2024n/an/a

-US$55m

Dec 31 2023US$2mUS$602k

-US$60m

Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$59m

Dec 31 2022US$3mUS$584k

-US$58m

Sep 30 2022n/an/a

-US$62m

Jun 30 2022n/an/a

-US$62m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$4mUS$509k

-US$43m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$46m

Dec 31 2020US$4mUS$470k

-US$50m

Sep 30 2020n/an/a

-US$60m

Jun 30 2020n/an/a

-US$60m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$785kUS$458k

-US$55m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$29m

Dec 31 2018US$1mUS$360k

-US$23m

Dec 31 2017US$851kUS$364k

-US$8m

Compensation vs Market: Joe's total compensation ($USD1.98M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.

CEO

Joe Oliveto (56 yo)

7.8yrs

Tenure

US$1,978,092

Compensation

Mr. Joseph G. Oliveto, also known as Joe, M.B.A. has been Chief Executive Officer and President of Milestone Pharmaceuticals Inc. March 2017 and has been its Director since July 2017. Mr. Oliveto served as...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Oliveto
CEO, President & Director7.8yrsUS$1.98m0.43%
$ 513.3k
Amit Hasija
CFO & Executive VP of Corporate Development5.3yrsUS$1.01m0.029%
$ 34.6k
David Bharucha
Chief Medical Officer2.8yrsUS$1.22m0.023%
$ 27.2k
Philippe Douville
Founderno datano datano data
Jeffrey Nelson
Chief Operating Officer4.5yrsno datano data
Kim Fox
Vice President of Communications1.3yrsno datano data
Roshan Girglani
Vice President of Marketingless than a yearno datano data
Jeff Moore
Vice President of Salesno datano datano data
Philip Sager
Chief Medical Advisor & Member of the Scientific Advisory Board4.9yrsno datano data
Guy Rousseau
SVP of Regulatory Affairs and Quality Managementno datano datano data
Lorenz Muller
Chief Commercial Officer7.2yrsUS$645.72k0.20%
$ 240.1k
Anita Holz
VP & Head of Medical Affairs2.3yrsno datano data

3.7yrs

Average Tenure

60yo

Average Age

Experienced Management: MIST's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Oliveto
CEO, President & Director7.4yrsUS$1.98m0.43%
$ 513.3k
Philippe Douville
Founder4.9yrsno datano data
Philip Sager
Chief Medical Advisor & Member of the Scientific Advisory Boardno datano datano data
Harry Leighton
Member of the Scientific Advisory Boardno datano datano data
Daniel Omstead
Observer7.3yrsno datano data
Harry Kopelman
Member of the Scientific Advisory Boardno datano datano data
Peter Kowey
Member of the Scientific Advisory Boardno datano datano data
John DiMarco
Member of the Scientific Advisory Boardno datano datano data
Paul Dorian
Member of the Scientific Advisory Boardno datano datano data
Michael Tomsicek
Independent Non-Executive Director5.7yrsUS$153.27k0.023%
$ 27.0k
John Camm
Member of the Scientific Advisory Boardno datano datano data
Robert Wills
Independent Chairman of the Board4.2yrsUS$176.77k0.023%
$ 27.0k

5.7yrs

Average Tenure

68yo

Average Age

Experienced Board: MIST's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 22:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Milestone Pharmaceuticals Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrick TrucchioH.C. Wainwright & Co.
Christopher HowertonJefferies LLC
Yuchen DingJefferies LLC